Trade-Ideas LLC identified

Agenus

(

AGEN

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Agenus as such a stock due to the following factors:

  • AGEN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $5.9 million.
  • AGEN has traded 195,533 shares today.
  • AGEN is trading at 3.02 times the normal volume for the stock at this time of day.
  • AGEN is trading at a new high 5.11% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AGEN with the Ticky from Trade-Ideas. See the FREE profile for AGEN NOW at Trade-Ideas

More details on AGEN:

Agenus Inc., an immuno-oncology company, focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer. Currently there are 5 analysts that rate Agenus a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Agenus has been 1.4 million shares per day over the past 30 days. Agenus has a market cap of $333.1 million and is part of the health care sector and drugs industry. Shares are down 9.7% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Agenus as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • AGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 25.78%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, AGENUS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • AGENUS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, AGENUS INC reported poor results of -$1.15 versus -$0.67 in the prior year. This year, the market expects an improvement in earnings (-$0.86 versus -$1.15).
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Biotechnology industry average. The net income increased by 39.9% when compared to the same quarter one year prior, rising from -$25.98 million to -$15.61 million.
  • AGEN's very impressive revenue growth greatly exceeded the industry average of 6.8%. Since the same quarter one year prior, revenues leaped by 371.8%. Growth in the company's revenue appears to have helped boost the earnings per share.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.